A study on human tissue and plasma led by researchers at USC Norris Comprehensive Cancer Center shows that their newly developed blood test, OvaPrint, may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.
Research from City of Hope and the Translational Genomics Research Institute, part of City of Hope, suggests that loss of a specific RNA molecule, miR-142, may lead to more aggressive forms of chronic myeloid leukemia.
Scientists at the Translational Genomics Research Institute, part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product-targeting antibody, for the treatment of pancreatic cancer.
A combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a recent study led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center found.
Study data from MAIA Biotechnology, Inc. showed that THIO (6-thio-dG or 6-thio-2’-deoxyguanosine), a first-in-class investigational telomere-targeting agent, demonstrates potent anticancer activity in diffuse intrinsic pontine glioma, one of the most aggressive tumors affecting the central nervous system in children.
The National Comprehensive Cancer Network has released a follow-up survey on the ongoing chemotherapy shortages: 72% of the centers surveyed continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin.
The American Society of Clinical Oncology has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials.
Researchers at Fox Chase Cancer Center demonstrated how amplification and rearrangement of a gene associated with leukemia, known as MLL, is directly controlled by epigenetic factors, providing needed insights into a new therapeutic opportunity.
City of Hope is initiating a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.
A team at Scripps Research and the Broad Institute of Harvard and MIT has discovered a new method to hone in on new drug targets most likely to impact multiple cancers.
